Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomic Cancer Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for METTL1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | METTL1 Recombinant Protein / METTL1-WDR4 Complex High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View METTL1 Products |
| Gene Delivery | METTL1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View METTL1 Products |
| Benchmark Ab | Anti-METTL1 Recombinant Antibody Recombinant positive control for Western Blot and IP. |
View METTL1 Products |
| Validator | METTL1 siRNA Set For knockdown verification in functional assays. |
View METTL1 Products |
| Related Target A | WDR4 Essential cofactor that stabilizes METTL1 and enhances tRNA m7G methyltransferase activity. |
View WDR4 Products |
| Related Target B | METTL3 Key m6A methyltransferase; crucial for cross-selectivity screening of RNA methyltransferase inhibitors. |
View METTL3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting physiological methyltransferase activity | Co-expressed METTL1/WDR4 complex proteins available with sequence-verified purity >95% |
| Selectivity screening against other RNA methyltransferases | Epitranscriptomic homolog panel (METTL3, METTL14, RNMT) strictly verified by mass spectrometry |
| Lack of Controls | Clinical benchmark antibodies and catalytic inactive mutants (D224A) included |
| False Positives | Validated siRNA sets included for target knockdown and specificity validation |
Live METTL1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for METTL1 therapeutics is intensifying, with major players shifting focus from traditional epitranscriptomic targets to m7G RNA methylation pathways. As first-generation METTL1 small molecule inhibitors reach preclinical optimization, the next wave of R&D is targeting the disruption of the METTL1-WDR4 complex interface to treat translationally deregulated cancers.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Accent Therapeutics, Storm Therapeutics | Hepatocellular Carcinoma (HCC), Glioblastoma, Solid Tumors | Enzymatic Assay (Need high-purity METTL1/WDR4 active complex) |
| PROTACs / Degraders | Academic Institutes, Biotech Startups | Myeloid Leukemias, Drug-Resistant Cancers | Ubiquitination & Degradation Assay (Need sequence-verified METTL1) |
| RNA Therapeutics (siRNA) | Alnylam (Exploratory), Custom Therapeutics | Intrahepatic Cholangiocarcinoma | Target Knockdown Validation (Need validated siRNA and qPCR controls) |